Log In
Print
BCIQ
Print
Print this Print this
 

rivipansel (GMI-1070, PF-06460031)

  Manage Alerts
Collapse Summary General Information
Company GlycoMimetics Inc.
DescriptionGlycomimetic inhibitor of E selectin (SELE; CD62E), P selectin (SELP; CD62P) and L selectin (CD62L; SELL)
Molecular Target E selectin (SELE) (CD62E) ; P selectin (SELP) (CD62P)
Mechanism of ActionPan-selectin antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationSickle cell disease
Indication DetailsPrevent or attenuate painful vaso-occlusive crisis and early death in sickle cell patients; Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease
Regulatory Designation

U.S. - Fast Track (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease);
U.S. - Orphan Drug (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease);
EU - Orphan Drug (Treat vaso-occlusive crisis (VOC) in patients with sickle cell disease)

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today